Form D · Biotechnology

Capsulomics, Inc.

Halethorpe, MD · CIK 0001800623

Offering snapshot reported Mar 19, 2025 · SEC filing

Reported sold
$2.39M
Offering amount: $3M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 17, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.2M$2.39MJan 22, 2020: $50,000.00Jan 22, 2020Mar 19, 2025: $2,392,270.00Mar 19, 2025

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$50,000 → $2,392,270
  • Reported investors2 → 10

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 19, 2025Amendment$2,392,270$2,342,270vs Jan 22, 202010SEC filing
Jan 22, 2020Initial$50,000No comparison2SEC filing

Offering details

Securities
Other
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-358725
Simple Agreement for Future Equity [SAFE]

Source: Form D, filed Mar 19, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Daniel Lunz Director, Executive
Stephen Meltzer Director
John Neiderhuber Director
William Stevens Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1450 S Rolling Road Suite 3 013
Halethorpe, MD, 21227